Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Constantine S. Tam, Judith Trotman, Stephen Opat, +18

Blood

Inhibition of Human Immunodeficiency Virus Type 1 Transcription by Chemical Cyclin-Dependent Kinase Inhibitors

Dai Wang, Cynthia de la Fuente, Longwen Deng, +9

Journal of Virology

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine S. Tam, Andrew Grigg, Stephen Opat, +13

Blood

Autophagy occurs upstream or parallel to the apoptosome during histolytic cell death

Fatih Akdemir, Róbert Farkas, Po Chen, +9

Development

Cell AutophagyMitophagySignal TransductionDevelopmental BiologySignaling Pathway +13

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development

Hexiang Wang, Bo Ren, Ye Liu, +31

Journal of Medicinal Chemistry

Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor

Na Li, Zhijian Sun, Ye Liu, +13

Cancer Research

Tyrosine KinaseImmunologyImmunotherapeuticsImmunotherapyTumor Biology +19

Antioxidant activity of Antrodia camphorata on free radical-induced endothelial cell damage

You-Cheng Hseu, Ssu‐Ching Chen, Yi-Jen Yech, +2

Journal of Ethnopharmacology

InflammationBiochemistryMedicineLipid PeroxidationPhysiology +9

Role of Prx1-expressing skeletal cells and Prx1-expression in fracture repair

A. Esposito, Lai Wang, Tieshi Li, +2

Bone

MechanobiologyRegenerative MedicineBone Morphogenic ProteinBone RepairFracture Healing +7

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Constantine S. Tam, Stephen Opat, Gavin Cull, +16

Blood

Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma

Carrie J. Li, Changying Jiang, Yang Liu, +11

Molecular Cancer Therapeutics